Additional class-related concerns include: Gallbladder disease , including cholelithiasis (gallstones) and cholecystitis, as observed with GLP-1 receptor agonist medicines [27] Dehydration and acute kidney injury (AKI) risk secondary to significant gastrointestinal fluid losses Increased heart rate , a recognised class effect of GLP-1 receptor agonists Pancreatitis a potential risk that warrants prompt medical assessment if severe abdominal pain develops Thyroid C-cell tumours observed in rodent studies with GLP-1 receptor agonists
Furthermore, these molecules also have extrapancreatic mechanisms of action that contribute to their glucose lowering properties, such as slow gastric emptying and increase satiety (Figure 1)
Supplied as lyophilised powder, third-party tested, lab certificate published on this page
Less daytime tiredness and other symptoms
A Personal Experience from the Canadian Peptide Community When I started Retatrutide last March, my main goal was dropping the 45 pounds I had gained since my 30s
It found 28.7% body-weight loss at 68 weeks on the 12 mg dose, alongside reduced knee osteoarthritis pain
